Literature DB >> 31295144

The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations.

Selena Hsin Feng1, Su-Tso Yang2.   

Abstract

The tumor, node, metastasis (TNM) staging system approved by International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC) to stage lung cancer was recently revised. The latest revision is the 8th edition published in January, 2017. This new edition made some important changes to the previous edition, including modification of the T classification based on 1 cm increment, downstage of T descriptor including endobronchial tumor disregarding its distance from carina (T2), merging total and partial atelectasis/pneumonitis into the same T category (T2), upstage diaphragmatic invasion to T4, new classification concept of adenocarcinoma in situ and minimally invasive adenocarcinoma for pure and part-solid ground-glass nodules, and further division of extrathoracic metastasis into M1b and M1c based on the number and sites of extrathoracic metastases. Consensus is reached for debating situations not covered in the previous edition of staging system, such as the classification of pancoast tumor based on its invasion depth and staging tumors that extend directly across the fissure as T2a. Classification of multiple sites of pulmonary involvement, including multiple primary lung cancer, separate lung cancer nodules, multiple ground-glass or lepidic lesions, and consolidation, is also discussed. Even though the 8th edition of the TNM lung staging system provides us with more precise classification based on prognostic analysis of each TNM descriptors, there are still some potential limitations and clinical situations that have not yet been clarified in terms of clinical staging by imaging. It is important for radiologists to understand the major changes introduced in the 8th edition of TNM staging and to recognize the potential pitfalls and limitations of imaging interpretation to precisely classify the clinical stage of lung cancer.

Entities:  

Mesh:

Year:  2019        PMID: 31295144      PMCID: PMC6622436          DOI: 10.5152/dir.2019.18458

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  11 in total

1.  A Case of Iodine 125 Seeds (I-125) Responding to Lung Squamous Cell Carcinoma.

Authors:  Qingtao Ni; Chi Pan; Qing Guo; Peng Wang; Yan Yang; Wei Zhang; Shengbin Dai
Journal:  Dose Response       Date:  2022-05-19       Impact factor: 2.623

2.  A Comprehensive Prognostic and Immune Analysis of Ferroptosis-Related Genes Identifies SLC7A11 as a Novel Prognostic Biomarker in Lung Adenocarcinoma.

Authors:  Li Qian; Fu Wang; Shu-Min Lu; Hua-Jie Miao; Xin He; Jia Feng; Hua Huang; Rong-Feng Shi; Jian-Guo Zhang
Journal:  J Immunol Res       Date:  2022-04-25       Impact factor: 4.493

Review 3.  Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review.

Authors:  Zhe Zhang; Sen Yang; Yanfang Ma; Hanqiong Zhou; Xuan Wu; Jing Han; Jiabao Hou; Lidan Hao; Jonathan D Spicer; Young Wha Koh; Mariano Provencio; Noemi Reguart; Tetsuya Mitsudomi; Qiming Wang
Journal:  Transl Lung Cancer Res       Date:  2021-06

4.  A case of haemoptysis and bilateral areas of lung consolidation sparing the right lower lobe.

Authors:  Nadia Corcione; Antonio Ponticiello; Severo Campione; Alfonso Pecoraro; Livio Moccia; Giuseppe Failla
Journal:  Breathe (Sheff)       Date:  2021-12

5.  Prognostic value of the immunohistochemistry markers CD56, TTF-1, synaptophysin, CEA, EMA and NSE in surgically resected lung carcinoid tumors.

Authors:  Vasiliki Epameinondas Georgakopoulou; Eleftherios Zygouris; Christos Damaskos; Aikaterini Pierrakou; Petros Papalexis; Nikolaos Garmpis; Aikaterini Aravantinou-Fatorou; Serafeim Chlapoutakis; Evangelos Diamantis; Christos Nikokiris; Aikaterini Gkoufa; Pagona Sklapani; Nikolaos Trakas; Jim Janinis; Demetrios A Spandidos; Jubrail Dahabreh
Journal:  Mol Clin Oncol       Date:  2021-12-14

6.  Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses.

Authors:  Valerio Gristina; Antonio Galvano; Luisa Castellana; Lavinia Insalaco; Stefania Cusenza; Giuseppa Graceffa; Federica Iacono; Nadia Barraco; Marta Castiglia; Alessandro Perez; Sergio Rizzo; Antonio Russo; Viviana Bazan
Journal:  Ther Adv Med Oncol       Date:  2021-07-21       Impact factor: 8.168

7.  Diagnostic value of circulating genetically abnormal cells to support computed tomography for benign and malignant pulmonary nodules.

Authors:  Han Yang; Hongjie Chen; Guorui Zhang; Hongyi Li; Ran Ni; Yali Yu; Yepeng Zhang; Yongjun Wu; Hong Liu
Journal:  BMC Cancer       Date:  2022-04-09       Impact factor: 4.430

8.  Simultaneous pathological findings in biopsy specimens of patients with surgically resected lung carcinoids and their role in survival.

Authors:  Vasiliki Epameinondas Georgakopoulou; Eleftherios Zygouris; Petros Papalexis; Aikaterini Gkoufa; Christos Damaskos; Aikaterini Pierrakou; Konstantinos Mantzouranis; Serafeim Chlapoutakis; Aikaterini Aravantinou-Fatorou; Pagona Sklapani; Nikolaos Trakas; Jim Janinis; Jubrail Dahabreh; Demetrios A Spandidos
Journal:  Oncol Lett       Date:  2022-07-15       Impact factor: 3.111

9.  Association between interleukin-36γ and tumor progression in non-small cell lung cancer.

Authors:  Lin Liu; Honghong He; Dan Xu; Yuehua Feng; Huijun Zhou; Liyan Shi; Yanzheng Gu; Jian Wang; Yibei Zhu
Journal:  Oncol Lett       Date:  2020-01-17       Impact factor: 2.967

10.  Machine Learning for the Prediction of Lymph Nodes Micrometastasis in Patients with Non-Small Cell Lung Cancer: A Comparative Analysis of Two Practical Prediction Models for Gross Target Volume Delineation.

Authors:  Shuli Hu; Man Luo; Yaling Li
Journal:  Cancer Manag Res       Date:  2021-06-17       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.